ioversol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 1471 87771-40-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ioversol
  • joversol
  • MP-328
  • Molecular weight: 807.12
  • Formula: C18H24I3N3O9
  • CLOGP: -2.73
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 8
  • TPSA: 199.89
  • ALOGS: -2.89
  • ROTB: 12
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
CL (Clearance) 1.47 mL/min/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
Vd (Volume of distribution) 0.21 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,MAPK9,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 39
kinase-selectivity-class ALK,AURKA,AURKC,AXL,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CLK2,CLK4,DYRK1B,EIF2AK3,EPHB4,FLT3,GAK,GRK2,GSK3A,GSK3B,IRAK1,IRAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK7,MARK4,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK10,STK17A,STK33,SYK,TEK,TGFBR1,TTK,TYRO3,UHMK1,ULK1,ULK2 52
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA LIEBEL-FLARSHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 632.34 60.52 316 4634 312418 90311079
Sneezing 368.78 60.52 113 4837 29756 90593741
Throat irritation 364.33 60.52 126 4824 48569 90574928
Pruritus 344.67 60.52 262 4688 541263 90082234
Dyspnoea 221.08 60.52 254 4696 880701 89742796
Throat tightness 219.10 60.52 76 4874 29408 90594089
Anaphylactic shock 198.81 60.52 72 4878 31545 90591952
Chest discomfort 171.92 60.52 102 4848 138263 90485234
Contrast media reaction 164.95 60.52 32 4918 1219 90622278
Erythema 162.63 60.52 119 4831 229127 90394370
Pharyngeal oedema 140.07 60.52 45 4905 13726 90609771
Laryngeal discomfort 114.14 60.52 20 4930 429 90623068
Air embolism 110.98 60.52 19 4931 354 90623143
Eye pruritus 110.70 60.52 46 4904 28981 90594516
Cough 106.36 60.52 115 4835 368847 90254650
Laryngeal oedema 97.49 60.52 29 4921 6852 90616645
Eye swelling 90.38 60.52 40 4910 29346 90594151
Type I hypersensitivity 78.91 60.52 22 4928 4133 90619364
Extravasation 76.53 60.52 20 4930 2944 90620553
Eyelid oedema 75.16 60.52 27 4923 11507 90611990
Rash 74.18 60.52 145 4805 795955 89827542
Bronchospasm 72.86 60.52 31 4919 20678 90602819
Drug ineffective 63.47 60.52 3 4947 1384295 89239202
Blood pressure decreased 62.40 60.52 43 4907 74852 90548645
Contrast media allergy 61.66 60.52 17 4933 3064 90620433
Rash maculo-papular 60.88 60.52 34 4916 40899 90582598

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 370.59 47.19 155 3032 73881 42544267
Sneezing 211.98 47.19 56 3131 6307 42611841
Pruritus 200.20 47.19 141 3046 188630 42429518
Anaphylactic shock 194.09 47.19 71 3116 23446 42594702
Nephropathy toxic 165.91 47.19 58 3129 16780 42601368
Contrast media reaction 135.05 47.19 28 3159 1088 42617060
Air embolism 105.80 47.19 18 3169 231 42617917
Throat irritation 98.73 47.19 37 3150 12999 42605149
Erythema 95.98 47.19 73 3114 108720 42509428
Dyspnoea 95.37 47.19 139 3048 442482 42175666
Throat tightness 86.60 47.19 31 3156 9568 42608580
Contrast encephalopathy 77.21 47.19 13 3174 156 42617992
Anaphylactic reaction 72.22 47.19 43 3144 42700 42575448
Laryngeal oedema 60.19 47.19 19 3168 3989 42614159
Cyanosis 53.77 47.19 25 3162 15006 42603142
Acute generalised exanthematous pustulosis 52.93 47.19 21 3166 8574 42609574
Hypersensitivity 51.76 47.19 43 3144 72327 42545821
Rash 49.38 47.19 80 3107 276874 42341274

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 716.10 46.72 360 6438 318497 110264004
Pruritus 401.00 46.72 310 6488 581250 110001251
Sneezing 392.95 46.72 124 6674 31860 110550641
Anaphylactic shock 368.45 46.72 133 6665 51413 110531088
Contrast media reaction 282.97 46.72 57 6741 2341 110580160
Throat irritation 276.61 46.72 109 6689 53443 110529058
Dyspnoea 217.19 46.72 300 6498 1106572 109475929
Erythema 214.17 46.72 162 6636 291285 110291216
Throat tightness 182.80 46.72 71 6727 33418 110549083
Air embolism 142.92 46.72 26 6772 614 110581887
Laryngeal oedema 136.97 46.72 42 6756 9765 110572736
Pharyngeal oedema 134.66 46.72 47 6751 16381 110566120
Laryngeal discomfort 131.41 46.72 25 6773 758 110581743
Type I hypersensitivity 118.13 46.72 34 6764 6359 110576142
Chest discomfort 117.23 46.72 92 6706 173756 110408745
Contrast encephalopathy 115.00 46.72 20 6778 362 110582139
Cyanosis 110.84 46.72 48 6750 29693 110552808
Cough 90.91 46.72 126 6672 461515 110120986
Extravasation 90.55 46.72 26 6772 4819 110577682
Eye swelling 90.41 46.72 43 6755 33005 110549496
Rash maculo-papular 89.18 46.72 56 6742 74166 110508335
Anaphylactic reaction 89.12 46.72 66 6732 114234 110468267
Contrast media allergy 85.22 46.72 23 6775 3400 110579101
Bronchospasm 84.72 46.72 40 6758 30199 110552302
Eye pruritus 84.66 46.72 41 6757 32734 110549767
Oxygen saturation decreased 82.64 46.72 72 6726 156910 110425591
Blood pressure decreased 82.06 46.72 63 6735 115028 110467473
Eyelid oedema 78.44 46.72 31 6767 15231 110567270
Loss of consciousness 76.23 46.72 76 6722 196230 110386271
Papule 71.69 46.72 26 6772 10107 110572394
Rash 71.35 46.72 156 6642 820808 109761693
Off label use 65.19 46.72 8 6790 1500177 109082324
Acute generalised exanthematous pustulosis 64.83 46.72 30 6768 21634 110560867
Shock 58.31 46.72 38 6760 53550 110528951
Procedural complication 57.35 46.72 21 6777 8384 110574117
Flushing 57.02 46.72 49 6749 104687 110477814
Cardio-respiratory arrest 56.67 46.72 51 6747 115785 110466716
Anaphylactoid reaction 53.89 46.72 19 6779 6807 110575694
Eosinophilia 53.25 46.72 37 6761 57899 110524602
Drug ineffective 51.48 46.72 15 6783 1520525 109061976
Hypersensitivity 51.03 46.72 90 6708 403908 110178593
Ocular hyperaemia 48.06 46.72 30 6768 39256 110543245
Face oedema 47.21 46.72 28 6770 33441 110549060

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AB07 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent

Related Drugs by ATC class:

V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media 11 drugs
iobitridoliodixanoliohexoliomeproliopamidoliopentoliopromideiotrolanioxaglic acidioxilanmetrizamide

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.63 acidic
pKa2 11.03 acidic
pKa3 11.71 acidic
pKa4 13.6 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020983 VUID
N0000148454 NUI
D01555 KEGG_DRUG
4020983 VANDF
C0063828 UMLSCUI
CHEBI:31717 CHEBI
CHEMBL1200614 ChEMBL_ID
DB09134 DRUGBANK_ID
C054871 MESH_SUPPLEMENTAL_RECORD_UI
6007 INN_ID
N3RIB7X24K UNII
3741 PUBCHEM_CID
27792 RXNORM
4909 MMSL
d01469 MMSL
003499 NDDF
109222009 SNOMEDCT_US
395759000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Optiray320 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1323 INJECTION 678 mg INTRA-ARTERIAL NDA 27 sections
Optiray320 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1323 INJECTION 678 mg INTRA-ARTERIAL NDA 27 sections
Optiray320 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1323 INJECTION 678 mg INTRA-ARTERIAL NDA 27 sections
Optiray300 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1332 INJECTION 636 mg INTRA-ARTERIAL NDA 27 sections
Optiray300 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1332 INJECTION 636 mg INTRA-ARTERIAL NDA 27 sections
Optiray300 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1332 INJECTION 636 mg INTRA-ARTERIAL NDA 27 sections
Optiray350 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1333 INJECTION 741 mg INTRA-ARTERIAL NDA 27 sections
Optiray350 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1333 INJECTION 741 mg INTRA-ARTERIAL NDA 27 sections
Optiray350 HUMAN PRESCRIPTION DRUG LABEL 1 0019-1333 INJECTION 741 mg INTRA-ARTERIAL NDA 27 sections